Mariner
CATX icon

Mariner’s Perspective Therapeutics CATX Stock Holding History

Mariner’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,815
Closed -$49.3K – 3570
2026
Q1 		$49.3K Buy
+11,815
New +$49.9K ﹤0.01% 3427
2025
Q4 		– Sell
-86,116
Closed -$295K – 3572
2025
Q3 		$295K Buy
86,116
+21,653
+34% +$78.9K ﹤0.01% 2822
2025
Q2 		$222K Buy
+64,463
New +$170K ﹤0.01% 2968
2025
Q1 		– Sell
-46,900
Closed -$150K – 3460
2024
Q4 		$150K Buy
+46,900
New +$383K ﹤0.01% 3087
2024
Q2 		– Sell
-4,778
Closed -$56.9K – 3187
2024
Q1 		$56.9K Hold
4,778
– – ﹤0.01% 3011
2023
Q4 		$19.2K Buy
+4,778
New +$13.4K ﹤0.01% 2999

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Mariner's CATX Position: Q2 2026 in Review

Mariner sold out of Perspective Therapeutics (CATX) in Q2 2026, closing a stake of 11,815 shares — an estimated $49.3K sold.

Mariner first reported a position in CATX in Q4 2023 and held it in 6 quarters. The position peaked at $295K in Q3 2025. 132 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • Mariner reported no remaining Perspective Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Mariner sold 11,815 Perspective Therapeutics shares in Q2 2026, an estimated $49.3K.
  • Mariner first reported a position in Perspective Therapeutics in Q4 2023 and held it in 6 quarters.
  • Mariner's Perspective Therapeutics position peaked at $295K in Q3 2025.
  • 132 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.